Isotechnika to provide strategic update



    EDMONTON, Jan. 16 /CNW/ - Isotechnika Inc. will provide a strategic
update via a live conference call on Thursday, January 17th at
10:30 a.m. ET/8:30 a.m. MT. The conference call is intended to provide
guidance on the Company's strategic direction and clinical development plan
moving forward. No new clinical trial data will be discussed during the
conference call. All interested parties will be able to access the live event
(audio only) through the Company's corporate web site at www.isotechnika.com.

    About Isotechnika
    -----------------
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential exceeds $2 billion annually in sales for
calcineurin inhibitors such as ISA247.
    ISA247 is currently being investigated in a Phase 2b North American trial
for the prevention of kidney graft rejection subsequent to transplantation and
a Phase 3 European/Canadian psoriasis trial.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at www.isotechnika.com.

    Partnerships with Isotechnika Inc.
    ----------------------------------
    Isotechnika Inc. signed a collaboration agreement with F. Hoffman-La
Roche and Hoffman-La Roche Inc. (collectively referred to as "Roche") on
April 9, 2002, which licensed the worldwide rights to develop and
commercialize ISA247 for all transplant indications. The collaboration
agreement was amended in April, 2004 allowing Roche to retain an option to
continue development of the transplant indications based on the successful
completion of the ongoing Phase 2b kidney transplant trial.
    On September 29, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the use of
ISA247 and TAFA93 specifically with drug eluting devices for the non-systemic
treatment of vascular, cardiovascular, target vessel and tissue disorders.
    Isotechnika and Cellgate Inc. ("Cellgate") signed an option agreement on
April 24, 2006, granting Isotechnika the option to obtain an exclusive license
to develop and commercialize conjugates consisting of Cellgate's patented
transporter technology for the topical delivery of ISA247 in patients
suffering from mild to moderate psoriasis.
    On May 24, 2006, Isotechnika signed an agreement with Lux Biosciences
Inc. ("Lux") granting Lux worldwide rights to develop and commercialize
Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all
ophthalmic diseases. Lux currently uses the code name LX211 for ISA247 for the
ophthalmic indications.

    Forward-Looking Statements
    --------------------------
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

    %SEDAR: 00010508E




For further information:

For further information: Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 487-1600 (x243), Fax: (780)
484-4105, E-mail: sgillis-paulgaard@isotechnika.com

Organization Profile

ISOTECHNIKA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890